• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Amyris Inc.

    2/9/24 9:12:55 PM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email
    S-8 POS 1 d65548ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on February 9, 2024

    Registration No. 333-266709

    Registration No. 333-258319

    Registration No. 333-239820

    Registration No. 333-234135

    Registration No. 333-225848

    Registration No. 333-224316

    Registration No. 333-217345

    Registration No. 333-210569

    Registration No. 333-203213

    Registration No. 333-195259

    Registration No. 333-188711

    Registration No. 333-187598

    Registration No. 333-180006

    Registration No. 333-172514

    Registration No. 333-169715

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-266709

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-258319

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-239820

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-234135

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225848

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224316

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-217345

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210569

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203213

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-195259

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-188711

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-187598

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-180006

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-172514

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-169715

     

     

    Amyris, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   55-0856151

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    5885 Hollis Street, Suite 100

    Emeryville, California 94608

      94608
    (Address of Principal Executive Offices)   (Zip Code)

    Amyris, Inc. 2020 Equity Incentive Plan

    Amyris, Inc. 2010 Equity Incentive Plan

    Amended and Restated 2010 Employee Stock Purchase Plan

    (Full title of the plan)

    Han Kieftenbeld

    Interim Chief Executive Officer and Chief Financial Officer

    Amyris, Inc.

    5885 Hollis Street, Suite 100

    Emeryville, California 94608

    (Name and address of agent for service)

    (510) 450-0761

    (Telephone number, including area code, of agent for service)

    Copies to:

    Gordon K. Davidson, Esq.

    Ryan Mitteness, Esq.

    Fenwick & West, LLP

    401 Union St.

    Seattle, Washington 98101

    (206) 389-4510

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by Amyris, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-8 (No. 333-266709), filed with the SEC on August 9, 2022;

     

      •  

    Registration Statement on Form S-8 (No. 333-258319), filed with the SEC on July 30, 2021;

     

      •  

    Registration Statement on Form S-8 (No. 333-239820), filed with the SEC on July 10, 2020;

     

      •  

    Registration Statement on Form S-8 (No. 333-234135), filed with the SEC on October 9, 2019;

     

      •  

    Registration Statement on Form S-8 (No. 333-225848), filed with the SEC on June 25, 2018;

     

      •  

    Registration Statement on Form S-8 (No. 333-224316), filed with the SEC on April 18, 2018;

     

      •  

    Registration Statement on Form S-8 (No. 333-217345), filed with the SEC on April 17, 2017;

     

      •  

    Registration Statement on Form S-8 (No. 333-210569), filed with the SEC on April 1, 2016;

     

      •  

    Registration Statement on Form S-8 (No. 333-203213), filed with the SEC on April 2, 2015;

     

      •  

    Registration Statement on Form S-8 (No. 333-195259), filed with the SEC on April 14, 2014;

     

      •  

    Registration Statement on Form S-8 (No. 333-188711), filed with the SEC on May 20, 2013;

     

      •  

    Registration Statement on Form S-8 (No. 333-187598), filed with the SEC on March 28, 2013;

     

      •  

    Registration Statement on Form S-8 (No. 333-180006), filed with the SEC on March 9, 2012;

     

      •  

    Registration Statement on Form S-8 (No. 333-172514), filed with the SEC on February 28, 2011; and

     

      •  

    Registration Statement on Form S-8 (No. 333-169715), filed with the SEC on October 1, 2010.

    On August 9, 2023, the Company and certain of its direct and indirect subsidiaries filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). On February 7, 2024, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Third Amended Joint Plan of Reorganization of Amyris, Inc. and Its Affiliated Debtors (the “Plan”). The Company expects that the effective date of the Plan will occur once all conditions precedent to the Plan have been satisfied.

    As a result of the Chapter 11 Cases and in accordance with the Plan, the Company has terminated all offerings of the Company’s common stock pursuant to the Registration Statements. Accordingly, effective upon filing of these Post-Effective Amendments, the Company hereby removes from registration all such shares of common stock of the Company that are registered but unsold under the Registration Statements, if any. Effective upon filing of these Post-Effective Amendments, the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such shares of common stock, and the Company hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on February 9, 2024. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

    AMYRIS, INC.

    /s/ Han Kieftenbeld

    Name:   Han Kieftenbeld
    Title:   Interim Chief Executive Officer and Chief Financial Officer
    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $AMRS
    Financials

    Live finance-specific insights

    See more
    • AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

      EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

      5/2/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

      Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

      3/15/23 4:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

      EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

      2/28/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

      Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

      8/9/23 9:38:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:14:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:12:50 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider White J. Scott

      3 - AMYRIS, INC. (0001365916) (Issuer)

      9/20/23 8:09:50 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Gund Philip J.

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:35:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Reiss M. Freddie

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:32:49 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      1/5/24 4:22:57 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      12/14/23 4:34:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      10/16/23 4:41:27 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Leadership Updates

    Live Leadership Updates

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

      EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re

      1/27/22 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials